|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CCDC86 |
Gene summary for CCDC86 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CCDC86 | Gene ID | 79080 |
| Gene name | coiled-coil domain containing 86 | |
| Gene Alias | CCDC86 | |
| Cytomap | 11q12.2 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q9H6F5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 79080 | CCDC86 | LZE4T | Human | Esophagus | ESCC | 3.29e-02 | 1.81e-02 | 0.0811 |
| 79080 | CCDC86 | LZE7T | Human | Esophagus | ESCC | 6.15e-06 | 5.30e-01 | 0.0667 |
| 79080 | CCDC86 | LZE8T | Human | Esophagus | ESCC | 8.93e-03 | 3.87e-02 | 0.067 |
| 79080 | CCDC86 | LZE24T | Human | Esophagus | ESCC | 2.40e-11 | 4.70e-01 | 0.0596 |
| 79080 | CCDC86 | LZE21T | Human | Esophagus | ESCC | 1.14e-06 | 1.05e-01 | 0.0655 |
| 79080 | CCDC86 | P2T-E | Human | Esophagus | ESCC | 4.90e-15 | 2.34e-01 | 0.1177 |
| 79080 | CCDC86 | P4T-E | Human | Esophagus | ESCC | 6.43e-22 | 7.40e-01 | 0.1323 |
| 79080 | CCDC86 | P5T-E | Human | Esophagus | ESCC | 4.98e-16 | 2.65e-01 | 0.1327 |
| 79080 | CCDC86 | P8T-E | Human | Esophagus | ESCC | 1.11e-08 | 1.50e-01 | 0.0889 |
| 79080 | CCDC86 | P9T-E | Human | Esophagus | ESCC | 1.14e-08 | 3.63e-01 | 0.1131 |
| 79080 | CCDC86 | P10T-E | Human | Esophagus | ESCC | 1.81e-13 | 1.89e-01 | 0.116 |
| 79080 | CCDC86 | P12T-E | Human | Esophagus | ESCC | 5.69e-14 | 4.66e-01 | 0.1122 |
| 79080 | CCDC86 | P15T-E | Human | Esophagus | ESCC | 1.94e-09 | 3.40e-01 | 0.1149 |
| 79080 | CCDC86 | P16T-E | Human | Esophagus | ESCC | 3.36e-13 | 2.70e-01 | 0.1153 |
| 79080 | CCDC86 | P17T-E | Human | Esophagus | ESCC | 6.30e-09 | 7.49e-01 | 0.1278 |
| 79080 | CCDC86 | P19T-E | Human | Esophagus | ESCC | 7.00e-03 | 1.02e+00 | 0.1662 |
| 79080 | CCDC86 | P20T-E | Human | Esophagus | ESCC | 1.15e-08 | 3.24e-01 | 0.1124 |
| 79080 | CCDC86 | P21T-E | Human | Esophagus | ESCC | 5.61e-18 | 5.78e-01 | 0.1617 |
| 79080 | CCDC86 | P22T-E | Human | Esophagus | ESCC | 3.27e-14 | 2.77e-01 | 0.1236 |
| 79080 | CCDC86 | P23T-E | Human | Esophagus | ESCC | 2.83e-20 | 6.58e-01 | 0.108 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CCDC86 | SNV | Missense_Mutation | novel | c.326N>G | p.Tyr109Cys | p.Y109C | Q9H6F5 | protein_coding | deleterious(0.03) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CCDC86 | SNV | Missense_Mutation | novel | c.772C>T | p.Leu258Phe | p.L258F | Q9H6F5 | protein_coding | deleterious(0.01) | benign(0.387) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| CCDC86 | SNV | Missense_Mutation | rs370580113 | c.821N>A | p.Arg274Gln | p.R274Q | Q9H6F5 | protein_coding | deleterious(0.05) | probably_damaging(0.946) | TCGA-A6-2672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| CCDC86 | SNV | Missense_Mutation | c.884N>T | p.Arg295Leu | p.R295L | Q9H6F5 | protein_coding | deleterious(0.04) | possibly_damaging(0.86) | TCGA-AG-3728-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | folinic | CR | |
| CCDC86 | SNV | Missense_Mutation | c.426N>T | p.Lys142Asn | p.K142N | Q9H6F5 | protein_coding | tolerated(0.05) | benign(0.154) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| CCDC86 | SNV | Missense_Mutation | rs376975583 | c.791G>A | p.Arg264His | p.R264H | Q9H6F5 | protein_coding | tolerated(0.2) | benign(0.001) | TCGA-AG-A026-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| CCDC86 | SNV | Missense_Mutation | novel | c.383N>T | p.Ser128Phe | p.S128F | Q9H6F5 | protein_coding | tolerated(0.19) | benign(0.017) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| CCDC86 | SNV | Missense_Mutation | novel | c.784N>T | p.Pro262Ser | p.P262S | Q9H6F5 | protein_coding | tolerated(0.05) | probably_damaging(0.964) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| CCDC86 | SNV | Missense_Mutation | rs769571200 | c.923N>A | p.Arg308His | p.R308H | Q9H6F5 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CCDC86 | SNV | Missense_Mutation | novel | c.182N>A | p.Arg61Lys | p.R61K | Q9H6F5 | protein_coding | tolerated(0.16) | benign(0.058) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |